The development and evaluation of triage algorithms for early discovery of adverse drug interactions

Drug Safety

Volumn 36, Issue 5, 2013, Pages 371-388

  Strandell, Johanna ^a,b   Caster, Ola ^a,c   Hopstadius, Johan ^a   Edwards, I Ralph ^a   Norén, G Niklas ^a,c  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ALGORITHM; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DATA BASE; DRUG INFORMATION; DRUG INTERACTION; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; EMERGENCY HEALTH SERVICE; ENZYME ACTIVITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; MEDICAL RESEARCH; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIGNAL DETECTION; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ALGORITHMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PROSPECTIVE STUDIES; ROC CURVE; TRIAGE;

EID: 84877781144     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0053-7     Document Type: Article

References (41)

1. Mjörndal T, Boman MD, Hägg S, Bäckstrom M, Wiholm BE, Wahlin A, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf. 2002;11(1):65-72.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-5.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9.
4. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998;316(7140):1295-8.
5. Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, et al. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Safety. 2010;33(8):667-75.
6. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiol Drug Saf. 2003;12(6):517-21.
7. Norén GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stats Med. 2008;27(16):3057-70.
8. Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64(4):489-95.
9. Strandell J, Caster O, Bate A, Norén GN, Edwards IR. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34(3):253-66.
10. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. 1994;10(2):93-102.
11. Baxter K, editor. Stockley's interaction alerts (including data up to April 2011). London: Pharmaceutical Press.
12. Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol. 2009;68(3):427-34.
13. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409-19.
14. Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Min Knowl Discov. 2007;14(3):305-28.
15. Strandell J, Wahlin S. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol. 2011;67(6):633-41.
16. Baxter K, editor. Stockley's drug interactions. 7th ed. London: Pharmaceutical Press; 2006.
17. DrugDex. Drug interactions. Thomson Reuters Healthcare MICROMEDEX 2.0. Available from URL: http://www.thomsonhc.com/home/. Accessed 15 Jun 2011.
18. PubMed, National Centre for Biotechnology Information. Available from URL: http://www.ncbi.nlm.nih.gov/pubmed/. Accessed 15 Jun 2011.
19. Drugdex. Thompson Micromedex database. Available from URL: http://www.thomsonhc.com. Accessed 15 Jun 2011.
20. Datapharm Communications Ltd. Electronic medicines compendium (electronic version). Available from URL: http://www.medicines.org.uk/. Accessed 15 June 2011.
21. CIOMS Working Group VIII. Practical aspects of signal detection in pharmacovigilance. Geneva: CIOMS; 2010.
22. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81.
23. Kovac M, Mitic G, Kovac Z. Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin. J Clin Pharm Ther. 2012;37(1):45-8.
24. Datapharm Communications Ltd. Electronic medicines compendium (electronic version). Product information for Tildiem. Available from: http://www. medicines.org.uk/. Accessed 15 April 2012.
25. Chatterjee A, Lahiri SN. Bootstrapping lasso estimators. J Am Stat Assoc. 2011;106(494):608-25.
26. Caster O. Automatic extraction of adverse drug reaction terms from medical free text. Annual conference of the International Society of Clinical Biostatistics (ISCB'09); 2009 Aug 26: Prague. Available from URL: http://www.iscb2009.info/RSystem/Soubory/Prez%20Wednesday/S33.1%20Caster.pdf. Accessed 15 Apr 2012.
27. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Series B Stat Methodol. 1996;58(1):267-88.
28. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68(19):1588-95.
29. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PloS one. 2006;1:e97.
30. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Statist Softw. 2010;33(1):1-22.
31. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, interference and prediction. Canada: Springer Science; 2001.
32. Wallach D, Goffinet B. Mean squared error of prediction as a criterion for evaluating and comparing system models. Ecol Modell. 1989;44:299-306.
33. Meyboom RH, Lindquist M, Flygare AK, Biriell C, Edwards IR. The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Saf. 2000;23(2):95-9.
34. MIMS annual: 30th edn. Sydney: MIMS Australia; 2006.
35. FASS. Interaktioner. Available from URL: http://www.fass.se/LIF/home/ index.jsp. Accessed 14 Oct 2011.
36. Flockhart table. Indiana University (updated 19 Aug 19 2009). Available from URL: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed 13 Oct 2011.
37. Drent M, Singh S, Gorgels AP, Hansell DM, Bekers O, Nicholson AG, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med. 2003;167(7):958-61.
38. Fleisch MC, Blauer F, Gubler JG, Kuhn M, Scherer TA. Eosinophilic pneumonia and respiratory failure associated with venlafaxine treatment. Eur Respir J. 2000;15(1):205-8.
39. Datapharm Communications Ltd. Electronic medicines compendium (electronic version). Product information for Losec. Available from: http://www.medicines. org.uk/. Accessed 15 Apr 2012.
40. Datapharm Communications Ltd. Electronic medicines compendium (electronic version) Product information for Kaletra. Available from: http://www.medicines. org.uk/. Accessed 15 Apr 2012.
41. Datapharm Communications Ltd. Electronic medicines compendium (electronic version). Product information for Zocor. Available from: http://www.medicines. org.uk/. Accessed 15 April 2012.